{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:26:07Z","timestamp":1761675967656},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":11013,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1982,6]]},"abstract":"<jats:p>1 Twenty outpatients with thyrotoxicosis received the non\u2010selective beta\u2010adrenoceptor antagonist nadolol as sole treatment for 3 weeks. 2 Clinical improvement as measured by reduction in thyrotoxicosis therapeutic index occurred during the first week of treatment and was continued thereafter, and was accompanied by a significant reduction in serum T3 and elevation of serum reverse T3. 3 As measured by reduction in exercise heart rate, during chronic dosing nadolol 160 mg once daily produced blockade of beta\u2010adrenoceptors for 12 h in all patients and 24 h in all but 2. 4 Wide interindividual variability was noted in steady state plasma nadolol concentrations, in part related to age and renal function. 5 Steady state plasma nadolol concentrations were related to reduction in heart rate.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1982.tb01875.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T16:53:19Z","timestamp":1343321599000},"page":"835-840","source":"Crossref","is-referenced-by-count":16,"title":["Nadolol in thyrotoxicosis."],"prefix":"10.1111","volume":"13","author":[{"given":"NR","family":"Peden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TE","family":"Isles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"IH","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Crooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00542321"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1974.tb00216.x"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(60)90334-2"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1979.tb01641.x"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.9"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6061.598"},{"key":"e_1_2_1_8_1","first-page":"184","article-title":"\u03b2\u2010blockers in thyrotoxicosis.","author":"MERCK","year":"1980","journal-title":"Lancet"},{"key":"e_1_2_1_9_1","first-page":"528","article-title":"Propranolol and the hypercalcaemia of thyrotoxicosis.","volume":"98","author":"FEELY J.","year":"1981","journal-title":"Acta Endocrinol. (Kbh)"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1979.tb02111.x"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.128"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-94-4-472"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198109173051206"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.281.6232.24"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1980.tb01056.x"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600660831"},{"key":"e_1_2_1_17_1","first-page":"699","volume-title":"The Thyroid","author":"JAVIT N.B.","year":"1978"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01314.x"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1980.tb03394.x"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1978246650"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1978.tb04590.x"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1976.tb00603.x"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb01048.x"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1975.tb00549.x"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1979.tb13463.x"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00561388"},{"key":"e_1_2_1_27_1","first-page":"67","article-title":"Radioimmunoassay of 3, 3\u2032, 5\u2032\u2010triiodothyronine (reverse T3) in unextracted human serum.","volume":"9","author":"RATCLIFFE W.A.","year":"1976","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197902153000707"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1978.tb03573.x"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(76)90394-6"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(69)91797-8"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)91873-3"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-44-5-1002"},{"key":"e_1_2_1_34_1","first-page":"51","volume-title":"International experience with nadolol, a long\u2010acting, \u03b2\u2010blocking agent","author":"WILKINSON R.","year":"1981"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1982.tb01875.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1982.tb01875.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T10:20:47Z","timestamp":1699698047000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1982.tb01875.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1982,6]]}},"alternative-id":["10.1111\/j.1365-2125.1982.tb01875.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1982.tb01875.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1982,6]]}}}